https://www.pharmaceutical-technology.com/data-insights/sar444656-sanofi-net-present-value-2/
SAR444656 is a small molecule commercialized by Sanofi, with a leading Phase II program in Hidradenitis Suppurativa.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/iti-1284-intra-cellular-therapies-net-present-value-2/
ITI-1284 is a small molecule commercialized by Intra-Cellular Therapies, with a leading Phase II program in Psychosis;Generalized Anxiety Disorder (GAD).
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-astrazeneca-net-present-value/?utm_source=lgp5-npv&utm_medium=24-182226&utm_campaign=recommended-articles-pi
Datopotamab deruxtecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Pre-Registration program in Non-Small Cell Lung Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/tyra-300-tyra-biosciences-net-present-value/
TYRA-300 is a small molecule commercialized by Tyra Biosciences, with a leading Phase II program in Metastatic Transitional (Urothelial) Tract Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/olanzapine-er-teva-pharmaceutical-industries-net-present-value/
Olanzapine ER is a small molecule commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Schizophrenia.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/livmoniplimab-abbvie-net-present-value-2/
Livmoniplimab is a monoclonal antibody commercialized by AbbVie, with a leading Phase III program in Non-Small Cell Lung Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/azetukalner-xenon-pharmaceuticals-net-present-value-2/
Azetukalner is a small molecule commercialized by Xenon Pharmaceuticals, with a leading Phase III program in Tonic-Clonic (Grand Mal) Seizure;Partial Seizure.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-net-present-value/
IK-595 is a small molecule commercialized by Ikena Oncology, with a leading Phase I program in Thyroid Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/puxitatug-samrotecan-astrazeneca-net-present-value-3/
Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Solid Tumor;Peritoneal Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/imdusiran-sodium-arbutus-biopharma-net-present-value/
Imdusiran Sodium is an antisense rnai oligonucleotide commercialized by Arbutus Biopharma, with a leading Phase II program in Hepatitis B.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/hs-20093-gsk-net-present-value/
HS-20093 is a monoclonal antibody conjugated commercialized by GSK, with a leading Phase I program in Solid Tumor.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/lonigutamab-ugodotin-acelyrin-net-present-value-2/
Lonigutamab Ugodotin is a monoclonal antibody commercialized by Acelyrin, with a leading Phase II program in Graves' Ophthalmopathy.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/gemcitabine-johnson-johnson-net-present-value/?utm_source=lgp5-npv&utm_medium=24-221218&utm_campaign=recommended-articles-pi
Gemcitabine is a small molecule commercialized by Johnson & Johnson, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC)...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/lemzoparlimab-i-mab-net-present-value/
Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/ata-3219-atara-biotherapeutics-net-present-value/
ATA-3219 is a gene-modified cell therapy commercialized by Atara Biotherapeutics, with a leading Phase I program in Diffuse Large B-Cell Lymphoma;Mantle Cell...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/transcon-il-2-beta-gamma-ascendis-pharma-net-present-value-2/
TransCon IL-2 beta/gamma is a recombinant protein commercialized by Ascendis Pharma, with a leading Phase II program in Human Papillomavirus (HPV) Associated...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/azetukalner-xenon-pharmaceuticals-net-present-value/
Azetukalner is a small molecule commercialized by Xenon Pharmaceuticals, with a leading Phase III program in Tonic-Clonic (Grand Mal) Seizure.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/sapablursen-sodium-ionis-pharmaceuticals-net-present-value-2/
Sapablursen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase II program in Polycythemia Vera.
net present valuerisk adjustedcurrentvaluation
https://cointelegraph.com/press-releases/safepal-and-morpho-bring-risk-adjusted-stablecoin-yield-to-self-custody-users
Jan 9, 2026 - The collaboration introduces Morpho Vaults to Ethereum, Base and Arbitrum natively within SafePal App, coupled with a Walletdrop campaign to boost cold-storage...
risk adjustedsafepalmorphobringstablecoin
https://www.rolandberger.com/en/Insights/Publications/Risk-adjusted-planning.html?btc=CN
How the risk-adjusted planning method we developed together with risk experts can help companies be better protected against existential threats in a volatile...
risk adjustedroland bergerplanning
https://www.pharmaceutical-technology.com/data-insights/mevidalen-hydroxybenzoate-eli-lilly-and-co-net-present-value/
Mevidalen Hydroxybenzoate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Lewy Body Dementia.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/eftilagimod-alfa-immutep-net-present-value/
Eftilagimod Alfa is a fusion protein commercialized by Immutep, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/lava-1207-lava-therapeutics-net-present-value/
LAVA-1207 is a monoclonal antibody commercialized by LAVA Therapeutics, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/deucrictibant-immediate-release-pharvaris-net-present-value/
Deucrictibant Immediate-release is a small molecule commercialized by Pharvaris, with a leading Phase III program in Hereditary Angioedema (HAE) (C1 Esterase...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-net-present-value-3/
Datopotamab deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Pre-Registration program in Human Epidermal Growth...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/gsk-4178116a-gsk-net-present-value/
GSK-4178116A is a live attenuated vaccine commercialized by GSK, with a leading Phase II program in Chicken Pox.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/nalbuphine-hydrochloride-er-trevi-therapeutics-net-present-value-2/
Nalbuphine Hydrochloride ER is a small molecule commercialized by Trevi Therapeutics, with a leading Phase III program in Pruritus.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/milvexian-bristol-myers-squibb-net-present-value/?utm_source=lgp5-npv&utm_medium=24-182096&utm_campaign=recommended-articles-pi
Milvexian is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Atrial Flutter.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/dexborneol-edaravone-simcere-pharmaceutical-group-net-present-value/
(Dexborneol + Edaravone) is a small molecule commercialized by Simcere Pharmaceutical Group, with a leading Phase I program in Acute Ischemic Stroke.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-net-present-value-2/
AFM-24I is a monoclonal antibody commercialized by Affimed, with a leading Phase II program in Solid Tumor.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/mazdutide-eli-lilly-and-co-net-present-value-2/
Mazdutide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/abbv-383-abbvie-net-present-value/
ABBV-383 is a monoclonal antibody commercialized by AbbVie, with a leading Phase II program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma.
net present valuerisk adjustedcurrentvaluation
https://www.prnewswire.com/news-releases/tanaka-capital-management-wins-2024-lseg-lipper-fund-award-for-best-risk-adjusted-three-year-performance-in-multi-cap-growth-fund-category-302095304.html
/PRNewswire/ -- Tanaka Capital Management today announced that it has received a 2024 LSEG Lipper Award for the TANAKA Growth Fund (TGFRX), which ranked...
capital managementtanakawinslseglipper
https://www.pharmaceutical-technology.com/data-insights/vtx-2735-ventyx-biosciences-net-present-value/
VTX-2735 is a small molecule commercialized by Ventyx Biosciences, with a leading Phase II program in Familial Cold Autoinflammatory Syndrome (Familial Cold...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/nemtabrutinib-merck-net-present-value/
Nemtabrutinib is a small molecule commercialized by Merck, with a leading Phase III program in Chronic Lymphocytic Leukemia (CLL).
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/diazoxide-choline-cr-soleno-therapeutics-net-present-value-2/
Diazoxide choline CR is a small molecule commercialized by Soleno Therapeutics, with a leading Pre-Registration program in Prader-Willi Syndrome (PWS).
net present valuerisk adjustedcurrentvaluation
https://marketrealist.com/2017/05/substantial-asia-exposure-improves-risk-adjusted-returns/
A higher allocation to Asia could certainly provide diversification benefits to investors while enhancing their risk-adjusted returns.
risk adjustedsubstantialasiaexposurecould
https://www.pharmaceutical-technology.com/data-insights/quavonlimab-merck-net-present-value/?utm_source=lgp5-npv&utm_medium=24-182258&utm_campaign=recommended-articles-pi
Quavonlimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/peresolimab-eli-lilly-and-co-net-present-value-2/
Peresolimab is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Autoimmune Disorders.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/inb-400-in8bio-net-present-value/
INB-400 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM).
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/imlunestrant-tosylate-eli-lilly-and-co-net-present-value/?utm_source=lgp5-npv&utm_medium=24-184127&utm_campaign=recommended-articles-pi
Imlunestrant tosylate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Metastatic Breast Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-net-present-value/
Rhenium (186Re) Obisbemeda is a small molecule commercialized by Plus Therapeutics, with a leading Phase II program in Leptomeningeal Disease (Neoplastic...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/tiragolumab-roche-net-present-value/?utm_source=lgp5-npv&utm_medium=24-329398&utm_campaign=recommended-articles-pi
Tiragolumab is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Esophageal Squamous Cell Carcinoma (ESCC).
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/rapcabtagene-autoleucel-novartis-net-present-value/?utm_source=lgp5-npv&utm_medium=24-184077&utm_campaign=recommended-articles-pi
Rapcabtagene autoleucel is a gene-modified cell therapy commercialized by Novartis, with a leading Phase II program in Relapsed Chronic Lymphocytic Leukemia...
net present valuerisk adjustedcurrentvaluation
https://thelawdictionary.org/risk-adjusted-return/
The rate-of-return, ROR, on an investment from which the ROR on a different investment is deducted as long as the risk is similar.
risk adjusted return
https://www.pharmaceutical-technology.com/data-insights/atumelnant-crinetics-pharmaceuticals-net-present-value/
Atumelnant is a small molecule commercialized by Crinetics Pharmaceuticals, with a leading Phase II program in Congenital Adrenal Hyperplasia (Adrenogenital...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/belrestotug-iteos-therapeutics-net-present-value/
Belrestotug is a monoclonal antibody commercialized by iTeos Therapeutics, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.ainvest.com/news/quantitative-hedge-evaluating-ietc-risk-adjusted-performance-tariff-policy-hedge-2601/
Quantitative Hedge: Evaluating IETC's Risk-Adjusted Performance as a Tariff Policy Hedge
risk adjustedquantitativehedgeevaluatingietc
https://www.pharmaceutical-technology.com/data-insights/auto-8-autolus-therapeutics-net-present-value/?utm_source=lgp5-npv&utm_medium=24-296880&utm_campaign=recommended-articles-pi
AUTO-8 is a gene-modified cell therapy commercialized by Autolus Therapeutics, with a leading Phase I program in Relapsed Multiple Myeloma;Refractory Multiple...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/gen-1184-genmab-net-present-value/
GEN-1184 is a monoclonal antibody conjugated commercialized by Genmab, with a leading Phase II program in Epithelial Ovarian Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/bavdegalutamide-arvinas-net-present-value/
Bavdegalutamide is a small molecule commercialized by Arvinas, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/cmg-901-astrazeneca-net-present-value/
CMG-901 is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal Junction.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/zelebrudomide-nurix-therapeutics-net-present-value/
Zelebrudomide is a small molecule commercialized by Nurix Therapeutics, with a leading Phase I program in Primary CNS Lymphoma.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/cft-7455-c4-therapeutics-net-present-value/
CFT-7455 is a small molecule commercialized by C4 Therapeutics, with a leading Phase II program in Anaplastic Large Cell Lymphoma (ALCL).
net present valuerisk adjustedcurrentvaluation
https://www.slideserve.com/stash/risk-adjusted-return-on-capital-raroc-for-a-credit-loan-portfolio-considering-soverign-risk
Risk Adjusted Return on Capital (RAROC) for a credit loan portfolio Considering soverign risk. Presented by Fernando Hernandez Consultant and instructor for...
risk adjusted returnpptcapitalraroccredit
https://www.pharmaceutical-technology.com/data-insights/hs-001-novo-nordisk-net-present-value/?utm_source=lgp5-npv&utm_medium=24-296874&utm_campaign=recommended-articles-pi
HS-001 is a cell therapy commercialized by Novo Nordisk, with a leading Phase II program in Systolic Heart Failure.
net present valuerisk adjustedcurrentvaluation
https://www.ainvest.com/news/vti-itot-quantitative-analysis-risk-adjusted-returns-portfolio-integration-2601/
VTI vs. ITOT: A Quantitative Analysis of Risk-Adjusted Returns and Portfolio Integration
quantitative analysisrisk adjustedvtivsitot
https://www.pharmaceutical-technology.com/data-insights/cardiamp-biocardia-net-present-value-3/
CardiAMP is a cell therapy commercialized by BioCardia, with a leading Phase III program in Systolic Heart Failure.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/bgb-3245-springworks-therapeutics-net-present-value/
BGB-3245 is a small molecule commercialized by SpringWorks Therapeutics, with a leading Phase II program in Metastatic Colorectal Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-celltrion-net-present-value-2/
Denosumab biosimilar is a monoclonal antibody commercialized by Celltrion, with a leading Pre-Registration program in Post Menopausal Osteoporosis.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/fhd-286-foghorn-therapeutics-net-present-value/
FHD-286 is a small molecule commercialized by Foghorn Therapeutics, with a leading Phase I program in Chronic Myelomonocytic Leukemia (CMML).
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/nipocalimab-johnson-johnson-net-present-value/
Nipocalimab is a monoclonal antibody commercialized by Johnson & Johnson, with a leading Phase III program in Acquired (Autoimmune) Hemolytic Anemia.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/vibostolimab-merck-net-present-value/
Vibostolimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/ponsegromab-pfizer-net-present-value/
Ponsegromab is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Congestive Heart Failure (Heart Failure).
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/gavorestat-applied-therapeutics-net-present-value-2/
Gavorestat is a small molecule commercialized by Applied Therapeutics, with a leading Pre-Registration program in Galactosemia.
net present valuerisk adjustedcurrentvaluation
https://www.mathworks.com/help/finance/risk-adjusted-return.html
This example shows how to use the risk-adjusted return to shift the risk of a portfolio to match the risk of a market portfolio or fund.
risk adjusted returnmatlab simulinkusing
https://www.pharmaceutical-technology.com/data-insights/navenibart-astria-therapeutics-net-present-value-2/
Navenibart is a monoclonal antibody commercialized by Astria Therapeutics, with a leading Phase II program in Hereditary Angioedema (HAE) (C1 Esterase...
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/ampligen-aim-immunotech-net-present-value/
Ampligen is an oligonucleotide commercialized by AIM ImmunoTech, with a leading Phase III program in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis).
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/ziltivekimab-novo-nordisk-net-present-value/
Ziltivekimab is a monoclonal antibody commercialized by Novo Nordisk, with a leading Phase III program in Inflammation.
net present valuerisk adjustedcurrentvaluation
https://www.pharmaceutical-technology.com/data-insights/vidofludimus-calcium-immunic-net-present-value/
Vidofludimus calcium is a small molecule commercialized by Immunic, with a leading Phase III program in Relapsing Remitting Multiple Sclerosis (RRMS).
net present valuerisk adjustedcurrentvaluation
https://www.ainvest.com/news/nvidia-palantir-ai-stock-offers-stronger-risk-adjusted-return-2026-2512/
Nvidia vs. Palantir: Which AI Stock Offers a Stronger Risk-Adjusted Return in 2026?
nvidiavspalantiraistock
https://www.pharmaceutical-technology.com/data-insights/frespaciguat-merck-net-present-value/
Frespaciguat is a small molecule commercialized by Merck, with a leading Phase III program in Idiopathic Pulmonary Hypertension.
net present valuerisk adjustedcurrentvaluation